What is Indaptus Therapeutics?
Headquartered in New York City, Indaptus Therapeutics operates as a clinical-stage biotechnology firm dedicated to transforming the treatment paradigm for oncology and infectious diseases. The company distinguishes itself through a unique mechanism that utilizes engineered, non-pathogenic gram-negative bacteria to prime both the innate and adaptive immune systems. By activating multiple immune pathways simultaneously, Indaptus aims to overcome the limitations of traditional monotherapies, offering a more robust and durable response against complex disease states. This innovative approach places the firm at the intersection of synthetic biology and immunology, providing a scalable platform for future therapeutic breakthroughs.
The company's strategic focus remains on translating its preclinical success into clinical validation, ensuring that its pipeline addresses significant unmet medical needs. By leveraging its proprietary technology, Indaptus is effectively positioning itself as a high-value player in the immunotherapy sector, attracting interest from institutional investors who recognize the potential for long-term clinical impact.
How much funding has Indaptus Therapeutics raised?
Indaptus Therapeutics has raised a total of $2.3M across 1 funding round:
Debt
$2.3M
Debt (2025): $2.3M with participation from Paulson Investment Company
Key Investors in Indaptus Therapeutics
Paulson Investment Company
Paulson Investment Company is a boutique investment banking and broker-dealer firm that focuses on serving small and mid-sized companies through capital markets expertise and long-term financial advisory services.
What's next for Indaptus Therapeutics?
The recent influx of capital is earmarked for the expansion of clinical trials and the optimization of the company's bacterial-based delivery systems. As Indaptus Therapeutics moves deeper into its clinical lifecycle, the focus will shift toward data readout milestones and potential regulatory engagement. The strategic backing provided by its investment partners will be instrumental in navigating the complexities of late-stage development and commercialization planning. Moving forward, the company is expected to prioritize the scaling of its manufacturing processes and the broadening of its therapeutic pipeline, ensuring that its immune-activating platform remains at the forefront of medical innovation. Investors will be closely monitoring the firm's ability to translate its unique biological approach into tangible patient outcomes, which will serve as the primary catalyst for future valuation growth.
See full Indaptus Therapeutics company page
